Skip to main content
View Cart

Migraine Pain Management

Current Pharmacological and Non-pharmacological Options

  • 1st Edition - October 24, 2024
  • Latest edition
  • Editor: Stephen B. Shrewsbury
  • Language: English

Migraine Management: Current Pharmacological and Non-pharmacological Options is a comprehensive guide to established, recent, and ongoing pharmaceuticals and device developme… Read more

Early spring sale

Nurture your knowledge

Grow your expertise with up to 25% off trusted resources.

Shop now

Description

Migraine Management: Current Pharmacological and Non-pharmacological Options is a comprehensive guide to established, recent, and ongoing pharmaceuticals and device development projects. The book provides detailed information on the historical developments of migraine pain management, druggable targets, drugs action mechanisms, drugs for acute treatment and preventive care of patients, administration routes, and alternative treatments. This is the ideal reference for academic researchers interested in anti-migraine pharmacology. It will also be a perfect reference for physicians and care professionals involved in the well-being of migraine patients.

Key features

  • Offers a comprehensive overview of pharmacological and alternative migraine pain treatment options
  • Covers the historical developments and current targets for drug development and delivery routes
  • Provides insights into comorbidities and their impact in patient compliance to treatment

Readership

Pharmaceutical/biotechnology researchers in academic and corporate environments, Research physicians, Neurologists, Headache specialists, Psychiatrists, Pain specialists and OBGYNs caring for women in the reproductive years (when migraine is most frequent), Social scientists, Health plan administrators and Health economists

Table of contents

Part I: Foundations and historical development of migraine pain management

1. Introduction

2. Neuroanatomy and Neurophysiology

3. Historical overview of migraine product development

4. Comorbidities and their impact on therapies

5. Not all Migraine attacks are the same

6. Challenges and Controversies; Pharmacokinetics, Linguistics, Semantics and Statistics

Part II: Druggable targets

7. CGRP

8. PACAP

9. Src family kinases (SFK) in Migraine

10. Delta opioid receptor system

11. Piezo channels in peripheral trigeminal nociception

12. TRP antagonists

Part III: Drugs – Acute Management

13. Simple analgesics and combination oral products

14. Cannabinoids & Phytochemicals

15. Ergots

16. Triptans

17. Beta blocker (timolol) eye drops

18. Lasmiditan (and the ditan class)

19. Gepants

Part IV: Drugs – Prevention

20. TCAs (Tricyclic Antidepresants), SNRIs, Beta blockers, candesartan, flunarizine

21. Antiseizure orals (gabapentin, topiramate)

22. Onabotulinumtoxin

23. Gepants (for prevention)

24. (CGRP) Monocloncal antibodies

Part V: Administration routes

25. Oral Drugs (including SMEDDS)

26. Inhaled - oral & nasal

27. Subcutaneous/IM/Transcutaneous ("Injectables")

28. IV/Infusion

Part VI: Alternative Management

29. The role of digital platforms and smartphone apps

30. Herbal Medicines

31. Phototherapy

32. Neuromodulation

33. Acupuncture (for episodic and chronic migraine)

34. Manual Therapies

35. Nutraceuticals and Diets

36. Mindfulness

Part VII: Summary & conclusion [Shrewsbury]

37. Final Perspectives: oral/non-oral pharmaceuticals; devices; Complimentary practices

Review quotes

"...offers a thorough overview of the history, pathophysiology, and available treatments for migraine, including both pharmacological and non-pharmacological approaches....[It] aims to give a thorough understanding of migraine as a disease and the latest advancements in the field of headache medicine,...offers a well-considered framework for those looking to build their foundational understanding of migraine pathophysiology and management,...[and] provides an extensive overview of migraine as a disease....The writing is well organized, easy to understand, and structured with a logical flow....written by authoritative figures in the field of headache medicine and contains a comprehensive review of migraine treatment options, book's organization and clarity make it an invaluable resource....It is an excellent supplement to existing literature and serves as a strong reference for healthcare providers seeking to enhance their understanding of treatment strategies....recommend[ed] for trainees and practicing clinicians looking to expand their fundamental knowledge on migraine." ©Doody's Review Service, 2025, Suraj Malhan, DO, MS (Thomas Jefferson University)

Product details

  • Edition: 1
  • Latest edition
  • Published: October 24, 2024
  • Language: English

About the editor

SS

Stephen B. Shrewsbury

Dr. Stephen Shrewsbury recently left Impel Pharmaceuticals where he served as Chief Medical Officer (CMO) from March 2017 and led the development of Precision Olfactory Delivery of DHE through its clinical program and to FDA approval in September 2021. Formerly Stephen was CMO at MAP Pharmaceuticals where he conducted a successful clinical program for an inhaled version of DHE, but it never got approved due to manufacturing issues. Before MAP he was at Chiron Corporation where he was also on the International Pharmaceutical Aerosol Consortium Board of Science. Before Chiron, Stephen spent 9 years with GlaxoSmithKline (last 2 in the US) having moved into the industry in 1993 after 13 years working in the UK’s National Health Service. He has also been CMO for several other West Coast (US) biotech companies; has numerous patents; written and published a book, over 40 scientific papers and nearly 200 abstracts
Affiliations and expertise
Formerly Impel Pharmaceuticals, USA

View book on ScienceDirect

Read Migraine Pain Management on ScienceDirect